Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

• Published in: Journal of translational medicine Vol. 18; no. 1; pp. 203 - 19
• Main Authors: Rogers, Christopher J., Harman, Robert J., Bunnell, Bruce A., Schreiber, Martin A., Xiang, Charlie, Wang, Fu-Sheng, Santidrian, Antonio F., Minev, Boris R.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.05.2020; BioMed Central; BMC
• Subjects: Adipocytes; Alveoli; Animal models; Animals; ARDS; Betacoronavirus - physiology; Bone marrow; Clinical trials; Clinical Trials as Topic; Coronavirus Infections - therapy; Coronaviruses; COVID-19; Cytokines; Edema; Epidemics; Fever; Health aspects; Humans; Hypoxia; Immune clearance; Immune response; Immunomodulation; Immunomodulators; Infections; Inflammation; Intravenous administration; Lung diseases; Medical research; Mesenchymal Stem Cell Transplantation - adverse effects; Mesenchymal stem cells; Mesenchymal Stem Cells - cytology; Morbidity; Mortality; Neutrophils; Outbreaks; Pandemics; Pathogenesis; Patients; Pneumonia; Pneumonia, Viral - therapy; Pulmonary fibrosis; Respiratory diseases; Respiratory distress syndrome; Respiratory function; Review; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Stem cell transplantation; Stem cells; United Kingdom; United Kingdom; COVID-19; Pneumonia; SARS-CoV-2; ARDS; Mesenchymal stem cells

In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that the rapidly spreading viral outbreak had become a gl...